Home › Funds › Bellevue Group AG › RLAY

Bellevue Group AG position in RLAY

RELAY THERAPEUTICS INC COM · Health Care

Bellevue Group AG reported holding 6,185,970 shares of RLAY (RELAY THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$115.7M, representing 2.44% of its reported portfolio and ranking #11 among its reported holdings. Bellevue Group AG has disclosed RLAY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)6.19M sh
Reported value held$115.74M
Portfolio Weight2.44%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's RLAY position evolved

Bellevue Group AG first disclosed a stake in RLAY in Q3 2023 at 4,885,000 shares (US$41.1M). The position peaked in Q2 2026 at 6,185,970 shares, worth US$115.7M. Across 12 filings, Bellevue Group AG increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 6,185,970 shares valued at US$115.7M — a reduction of -1,609,272 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.88M $41.08M New
Q4 2023 5.94M $65.36M Add
Q1 2024 5.93M $49.19M Hold
Q2 2024 6.38M $41.58M Add
Q3 2024 7.38M $52.23M Add
Q4 2024 7.38M $30.39M Hold
Q1 2025 7.38M $19.33M Hold
Q2 2025 8.23M $28.48M Add
Q3 2025 8.35M $43.56M Add
Q4 2025 8.35M $70.60M Hold
Q1 2026 7.80M $77.56M Reduce
Q2 2026 6.19M $115.74M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RLAY and 13F data

RLAY (RELAY THERAPEUTICS INC COM) is a Health Care company. 64 other funds we track also report a position in RLAY — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$522.1M), Casdin Capital (US$300.0M), PERCEPTIVE ADVISORS LLC (US$263.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RLAY

All RLAY fund holders →

FAQ

How long has Bellevue Group AG held RLAY?

Bellevue Group AG has disclosed RLAY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in RLAY?

As of Q2 2026, Bellevue Group AG holds 6.19M shares of RLAY (RELAY THERAPEUTICS INC COM), valued at $115.74M, representing 2.44% of its reported portfolio and ranking #11.

Has Bellevue Group AG been buying or selling RLAY?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in RLAY. The position peaked in Q2 2026 at 6.19M shares.

Which other funds hold RLAY?

Other major institutional holders of RLAY include SB INVESTMENT ADVISERS (UK) LTD, Casdin Capital, PERCEPTIVE ADVISORS LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.